One in SIX cancer patients miss out on vital cancer drugs, a report reveals

0
23
One in SIX cancer patients miss out on vital cancer drugs, a report reveals



ONE in six cancer patients are missing out on drugs their doctors want to prescribe, a report reveals.
Lives are being put at risk as treatments are not available on the NHS or only in limited circumstances.
Getty – Contributor One in six cancer patients aren’t getting the drugs that their doctors want to prescribe, a report reveals
Experts blame the high cost of new medicines, the slow regulation process and outdated appraisal methods for delays in approval for use.
The Institute of Cancer Research is calling for urgent action to ensure patients get faster access to the latest drugs.
The charity has put forward an action plan after it polled more than 1,000 cancer patients on their access to new therapies.
‘HIGH PRICES OF CANCER DRUGS’
Twelve per cent said they faced delays in getting drugs recommended by their doctor and nine per cent were denied a treatment entirely.
One in six patients fell into one or both categories.
And 70 per cent think prices charged by pharma companies for new treatments is “much too high” with some cancer drugs costing £3,500 a month.
Half of those trying to enrol in clinical trials were rejected.
VACCINE PANIC Fears of measles ‘timebomb’ as 500k kids miss MMR jabs after scare stories clap hands! Tiny blisters on woman’s hand turn out to gonorrhoea that had spread WarningRASH HORROR Man’s scaly rash over face, back & genitals was ‘highly contagious scabies’ DECADES asleep Mum wakes from a coma after 27 YEARS & calls name of son she saved in crash RED ALERT Saharan dust cloud engulfing UK could trigger deadly asthma attacks, experts warn SWITCH OFF Kids under 2 ‘should never be allowed to watch ANY screens – or they’ll get fat’
The ICR wants all patients to be able to access trials, as well as action to bring down prices and more flexible regulation.
Chief exec Professor Paul Workman said: “Our manifesto calls for action to supercharge the passage of the most innovative cancer drugs through clinical trials, licensing and appraisal, and into the NHS.
“It is crucial also to address the extremely high prices of cancer drugs.”
Getty – Contributor 70 per cent of patients thought that prices charged by pharma companies for new treatments were too high
Mum of seven with stage four breast cancer plans bucket list

 
 

LEAVE A REPLY

Please enter your comment!
Please enter your name here